- PLN23.67m
- PLN16.73m
- PLN2.39m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.58 | ||
| Price to Tang. Book | 2.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.15% | ||
| Return on Equity | -22.1% | ||
| Operating Margin | -176.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 0.2 | 20.47 | 23.2 | 10.59 | 2.39 | n/a | n/a | 111.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +22.57 | -94.22 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genxone SA is a Poland-based company, which specializes in NGS (next generation sequencing) and medical diagnostics. The Company is involved in the development and marketing of nanoforming technology in the field of science, business and medicine and cooperates as a commercial partner with Oxford Nanopore Technologies - biotechnological innovation entity.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 8th, 2018
- Public Since
- August 12th, 2020
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 3,296,600
- Address
- ul. Kobaltowa 6, Zlotniki, SUCHY LAS K/POZNANIA W., 62-002
- Web
- https://genxone.eu/
- Phone
- Auditors
- Andrzej Furmanowski
Upcoming Events for GX1
Similar to GX1
Bioceltix SA
Warsaw Stock Exchange
Biogened SA
Warsaw Stock Exchange
BioMaxima SA
Warsaw Stock Exchange
Cannabis Poland SA
Warsaw Stock Exchange
Celon Pharma SA
Warsaw Stock Exchange
FAQ
As of Today at 19:09 UTC, shares in Genxone SA are trading at PLN7.18. This share price information is delayed by 15 minutes.
Shares in Genxone SA last closed at PLN7.18 and the price had moved by -16.51% over the past 365 days. In terms of relative price strength the Genxone SA share price has underperformed the FTSE Global All Cap Index by -21.62% over the past year.
There is no consensus recommendation for this security.
Genxone SA does not currently pay a dividend.
Genxone SA does not currently pay a dividend.
Genxone SA does not currently pay a dividend.
To buy shares in Genxone SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN7.18, shares in Genxone SA had a market capitalisation of PLN23.67m.
Here are the trading details for Genxone SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: GX1
Based on an overall assessment of its quality, value and momentum Genxone SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genxone SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -10.78%.
As of the last closing price of PLN7.18, shares in Genxone SA were trading -0.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genxone SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN7.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Genxone SA's directors